Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects

A promising strategy for cancer immunotherapy is to disrupt key pathways regulating immune tolerance, such as cytotoxic T lymphocyte–associated protein 4 (CTLA-4). However, the determinants of response to anti–CTLA-4 mAb treatment remain incompletely understood. In murine models, anti–CTLA-4 mAbs al...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ruocco, Maria Grazia, Pilones, Karsten A., Kawashima, Noriko, Cammer, Michael, Huang, Julie, Babb, James S., Liu, Mengling, Formenti, Silvia C., Dustin, Michael L., Demaria, Sandra
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2012
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461908/
https://ncbi.nlm.nih.gov/pubmed/22945631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI61931
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы